Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on advancing novel therapeutics for pain and neuropathy. The company's mission is to develop new non-opioid medicines to address significant unmet medical needs in these areas. Headquartered in Alpharetta, Georgia, Dogwood Therapeutics operates within the biopharmaceutical sector.

The company's lead product candidate is Halneuron®, a highly selective sodium channel blocker currently in Phase 2b development. Halneuron® is being developed to treat moderate-to-severe chemotherapy-induced neuropathic pain (CINP), cancer-related pain (CRP), and other pain indications, and has received Fast Track designation from the FDA for CINP. Dogwood Therapeutics' pipeline also includes SP16 IV, an LRP1 agonist with potential to treat neuropathy and repair nerve damage following chemotherapy, with a Phase 1b CINP trial fully funded by the National Cancer Institute. Additionally, from its formation through a merger, the company holds assets such as IMC-1 for fibromyalgia, poised for Phase 3 development, and IMC-2 for Long-COVID sequelae, currently in Phase 2 development.

Dogwood Therapeutics became publicly traded on the Nasdaq Capital Market under the ticker symbol DWTX in October 2024, following a combination of Virios Therapeutics and Sealbond Limited. Recent developments include the appointment of Iain Dukes as Chair of its Scientific Advisory Board in June 2026 and the commencement of a Halneuron® Phase 2b Long Term Extension Study in May 2026. The company also announced positive interim Phase 2b clinical trial results for Halneuron® in CINP in December 2025. Greg Duncan serves as the Chief Executive Officer and Chairman of the Board.